非布司他的用法和用量

Febuxostat (febuxostat, feburic) is a xanthine oxidase (XO) inhibitor indicated for the chronic management of patients with hyperuricemic gout. Gout occurs due to excessive production of uric acid in the body and reduced kidney clearance ability. Uric acid accumulates in the body, leading to the deposition of urate crystals in joints and various organs. Therefore, gout is usually treated by promoting uric acid excretion and inhibiting uric acid production, and taking appropriate measures to improve related symptoms. The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Febuxostat (febuxostat, feburic) is the latest XOR inhibitor developed in the world. It acts on this oxidase highly selectively, reducing the synthesis of uric acid in the body and lowering the concentration of uric acid, thereby effectively treating gout.  

Febuxostat (febuxostat, feburic) is an effective non-purine selective inhibitor of xanthine oxidase (XO). By selectively inhibiting xanthine oxidase, it can achieve the therapeutic effect of reducing serum uric acid. Uric acid is the end product of purine metabolism and is produced in the cascade reaction of hypoxanthine → xanthine → uric acid. Each step of the conversion is catalyzed by xanthine oxidase. Febuxostat (febuxostat, feburic) has been shown to effectively inhibit both oxidized and reduced forms of xanthine oxidase. Febuxostat (febuxostat, feburic) at therapeutic concentrations does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotate monophosphate decarboxylase, or purine nucleoside phosphorylase.  

The recommended oral dose of febuxostat (febuxostat, feburic) is 40 mg or 80 mg once daily. The recommended starting dose of febuxostat (febuxostat, feburic) is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 µmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Special groups such as patients with hepatic insufficiency: Patients with mild or moderate hepatic insufficiency (Child-Pugh A, B) do not need to adjust the dosage. The efficacy and safety of febuxostat (febuxostat, feburic) have not been studied in patients with severe hepatic insufficiency (Child-Pugh class C). Therefore, febuxostat (febuxostat, feburic) should be used with caution in these patients.